Compare GHG & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
GreenTree Hospitality Group Ltd. American depositary shares each representing one ordinary share
Current Price
Current Price
| Metric | GHG | ICCC |
|---|---|---|
| Founded | 2004 | 1982 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.0M | 93.1M |
| IPO Year | 2017 | 1995 |
| Metric | GHG | ICCC |
|---|---|---|
| Price | $1.08 | $10.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.2K | ★ 26.2K |
| Earning Date | 04-29-2026 | 05-15-2026 |
| Dividend Yield | ★ 4.15% | N/A |
| EPS Growth | N/A | ★ 53.85 |
| EPS | N/A | ★ 0.41 |
| Revenue | N/A | ★ $26,493,169.00 |
| Revenue This Year | $19.02 | N/A |
| Revenue Next Year | $8.26 | N/A |
| P/E Ratio | ★ $5.76 | $24.61 |
| Revenue Growth | N/A | ★ 51.64 |
| 52 Week Low | $1.08 | $4.52 |
| 52 Week High | $2.57 | $12.10 |
| Indicator | GHG | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 45.12 | 41.22 |
| Support Level | $1.10 | $9.27 |
| Resistance Level | $1.16 | $10.75 |
| Average True Range (ATR) | 0.02 | 0.51 |
| MACD | -0.00 | -0.13 |
| Stochastic Oscillator | 37.50 | 28.98 |
GreenTree Hospitality Group Ltd is a franchised hotel operator in China as franchised and managed hotels represent almost all the hotels in its hotel network. The company operates its hotels under GreenTree Inns, GreenTree Eastern, Gme, Gya and VX, GreenTree Alliance, Vatica, and others. The Group reports its financial results in two operating segments: Hotel Business, which consists of leased-and-operated hotels and franchised-and-managed hotels operating under the hotel related brand, and Restaurant Business, which consists of leased-and-operated restaurants and franchised-and-managed restaurants operating under the brands of Da Niang and Bellagio. It derives maximum revenue from Hotel Business segment. It operates solely in China and generates all its revenue from China itself.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.